Literature DB >> 22831772

Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging.

Nathan L Hutcheson1, Meredith A Reid, David M White, Nina V Kraguljac, Kathy B Avsar, Mark S Bolding, Robert C Knowlton, Jan A den Hollander, Adrienne C Lahti.   

Abstract

BACKGROUND: Studies have shown that individuals with schizophrenia suffer from memory impairments. In this study, we combined proton magnetic resonance spectroscopy (¹H-MRS) and functional magnetic resonance imaging (fMRI) to clarify the neurobiology of memory deficits in schizophrenia.
METHODS: We used single-voxel MRS acquired in the left hippocampus and fMRI during performance of a memory task to obtain measures of neurochemistry and functional response in 28 stable, medicated participants with schizophrenia (SZ) and 28 matched healthy controls (HC).
RESULTS: The SZ group had significantly decreased blood oxygen level-dependent (BOLD) signal in left inferior frontal gyrus (IFG) during encoding and in the anterior cingulate cortex (ACC) and superior temporal gyrus (STG) during retrieval. We did not find significant differences in N-acetylaspartate/creatine (NAA/Cr) or glutamate+glutamine (Glx/Cr) levels between the groups, but did find a significant positive correlation between NAA/Cr and Glx/Cr in the HC group that was absent in the SZ group. There were no significant correlations between BOLD and MRS measured in the hippocampus. Further analyses revealed a negative correlation between left IFG BOLD and task performance in the SZ group. Finally, in the HC group, the left IFG BOLD was positively correlated with Glx/Cr.
CONCLUSIONS: We replicated findings of reduced BOLD signal in left IFG and of an altered relationship between IFG BOLD response and task performance in the SZ. The absence of correlation between NAA/Cr and Glx/Cr levels in patients might suggest underlying pathologies of the glutamate-glutamine cycle and/or mitochondria.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22831772      PMCID: PMC3482548          DOI: 10.1016/j.schres.2012.06.039

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  47 in total

Review 1.  Episodic memory-related activation in schizophrenia: meta-analysis.

Authors:  Amélie M Achim; Martin Lepage
Journal:  Br J Psychiatry       Date:  2005-12       Impact factor: 9.319

2.  Effect of schizophrenia on frontotemporal activity during word encoding and recognition: a PET cerebral blood flow study.

Authors:  J D Ragland; R C Gur; J Raz; L Schroeder; C G Kohler; R J Smith; A Alavi; R E Gur
Journal:  Am J Psychiatry       Date:  2001-07       Impact factor: 18.112

3.  False discovery rate revisited: FDR and topological inference using Gaussian random fields.

Authors:  Justin R Chumbley; Karl J Friston
Journal:  Neuroimage       Date:  2008-05-23       Impact factor: 6.556

4.  Improved method for accurate and efficient quantification of MRS data with use of prior knowledge

Authors: 
Journal:  J Magn Reson       Date:  1997-11       Impact factor: 2.229

5.  Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study.

Authors:  Ludger Tebartz van Elst; Gabi Valerius; Martin Büchert; Thorsten Thiel; Nicholas Rüsch; Emanuel Bubl; Jürgen Hennig; Dieter Ebert; Hans M Olbrich
Journal:  Biol Psychiatry       Date:  2005-07-14       Impact factor: 13.382

6.  Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain.

Authors:  Margaret R Lentz; John P Kim; Susan V Westmoreland; Jane B Greco; Robert A Fuller; Eva M Ratai; Julian He; Prabhat K Sehgal; Elkan F Halpern; Andrew A Lackner; Eliezer Masliah; R Gilberto González
Journal:  Radiology       Date:  2005-03-29       Impact factor: 11.105

Review 7.  Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis.

Authors:  Stefan Brugger; John M Davis; Stefan Leucht; James M Stone
Journal:  Biol Psychiatry       Date:  2010-12-08       Impact factor: 13.382

8.  Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?

Authors:  Terry E Goldberg; Robert S Goldman; Katherine E Burdick; Anil K Malhotra; Todd Lencz; Raman C Patel; Margaret G Woerner; Nina R Schooler; John M Kane; Delbert G Robinson
Journal:  Arch Gen Psychiatry       Date:  2007-10

Review 9.  Prefrontal activation deficits during episodic memory in schizophrenia.

Authors:  John D Ragland; Angela R Laird; Charan Ranganath; Robert S Blumenfeld; Sabina M Gonzales; David C Glahn
Journal:  Am J Psychiatry       Date:  2009-05-01       Impact factor: 18.112

10.  The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and anhedonia in major depression.

Authors:  Martin Walter; Anke Henning; Simone Grimm; Rolf F Schulte; Johannes Beck; Ulrike Dydak; Betina Schnepf; Heinz Boeker; Peter Boesiger; Georg Northoff
Journal:  Arch Gen Psychiatry       Date:  2009-05
View more
  37 in total

1.  A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia.

Authors:  Meredith A Reid; David M White; Nina V Kraguljac; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2015-12-21       Impact factor: 4.939

Review 2.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

Review 3.  Postmortem studies on mitochondria in schizophrenia.

Authors:  Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2017-02-09       Impact factor: 4.939

4.  Hippocampal-parietal dysconnectivity and glutamate abnormalities in unmedicated patients with schizophrenia.

Authors:  Nina Vanessa Kraguljac; David Matthew White; Jennifer Hadley; Meredith Amanda Reid; Adrienne Carol Lahti
Journal:  Hippocampus       Date:  2014-08-01       Impact factor: 3.899

Review 5.  [Neurobiology of schizophrenia: new findings from the structure to the molecules].

Authors:  A Schmitt; B Malchow; D Keeser; P Falkai; A Hasan
Journal:  Nervenarzt       Date:  2015-03       Impact factor: 1.214

Review 6.  Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Authors:  Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis
Journal:  Schizophr Res       Date:  2014-01-11       Impact factor: 4.939

7.  Evidence for regional hippocampal damage in patients with schizophrenia.

Authors:  Sadhana Singh; Subash Khushu; Pawan Kumar; Satnam Goyal; Triptish Bhatia; Smita N Deshpande
Journal:  Neuroradiology       Date:  2017-12-11       Impact factor: 2.804

8.  Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study.

Authors:  Nina Vanessa Kraguljac; David Matthew White; Nathan Hadley; Jennifer Ann Hadley; Lawrence Ver Hoef; Ebony Davis; Adrienne Carol Lahti
Journal:  Schizophr Bull       Date:  2016-02-12       Impact factor: 9.306

9.  A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia.

Authors:  Nina V Kraguljac; Charity J Morgan; Meredith A Reid; David M White; Ripu D Jindal; Soumya Sivaraman; Bridgette K Martinak; Adrienne C Lahti
Journal:  Schizophr Res       Date:  2019-01-07       Impact factor: 4.939

10.  Cross-sectional Study of Glutamate in the Anterior Cingulate and Hippocampus in Schizophrenia.

Authors:  Jürgen Gallinat; Kibby McMahon; Simone Kühn; Florian Schubert; Martin Schaefer
Journal:  Schizophr Bull       Date:  2015-09-02       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.